<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295317</url>
  </required_header>
  <id_info>
    <org_study_id>B2019-276</org_study_id>
    <nct_id>NCT04295317</nct_id>
  </id_info>
  <brief_title>PD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery</brief_title>
  <official_title>Eﬀect of PD-1 Antibody (SHR-1210) Combined With Apatinib and Capecitabine Treatment After Resection of Intrahepatic Cholangiocarcinoma With High Risk of Recurrence : a Phase 2 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an
      open- label,single center,non-randomized ,single arm exploratory study . This clinical study
      is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate
      the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 plus Apatinib and
      Capecitabine in patients with Intrahepatic Cholangiocarcinoma After Surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>From the date of liver surgery to the date of diagnosis of tumor recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>From the date of liver surgery to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the potential side effects</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Combined the therapy using Apatinib,Capecitabine and PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis) Capecitabine 1500mg / m2, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis) Apatinib 250mg /d Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib 250mg /d; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)</description>
    <arm_group_label>Combined the therapy using Apatinib,Capecitabine and PD-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 blocking antibody SHR-1210</intervention_name>
    <description>PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)</description>
    <arm_group_label>Combined the therapy using Apatinib,Capecitabine and PD-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)</description>
    <arm_group_label>Combined the therapy using Apatinib,Capecitabine and PD-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age:18-75 years, male or femal;

          -  Intrahepatic Cholangiocarcinoma confirmed by histopathology, R0 resection was
             classified as Stage II, Stage IIIA and Stage IIIB according to AJCC TNM (8th edition,
             2017);

          -  No extrahepatic metastases;

          -  preoperative assessment of Child-Pugh A，ECOG Performance Status 0-1;

          -  Subjects with chronic HBV infection must have HBV-DNA &lt;500 IU / ml;

          -  Functional indicators of vital organs meet the following requirements: Neutrophils
             ≥1.5*109/L; platelets≥50*109/L; hemoglobin≥90g/l; Alanine aminotransferase （ALT） and
             Aspartate aminotransferase （AST） ≤ 2.5 times ULN,total bilirubin≤1.5 ULN;
             International standardized ratio (INR) ≤2.3ULN,creatinine ≤1.5 ULN;

          -  No tumor recurrence or metastasis was observed.

        Exclusion Criteria:

          -  Pathological diagnosis of hepatocellular carcinoma, mixed liver cancer, hilar bile
             duct cancer;

          -  No anti-tumor treatment for Intrahepatic Cholangiocarcinoma, including chemotherapy
             and topical treatment, before surgery;

          -  Known history of hypersensitivity to macromolecular protein preparation or any
             components of the SHR- 1210 formulation;

          -  Tumors are not completely removed, or postoperative pathology suggests
             non-Intrahepatic Cholangiocarcinoma or other malignant components;

          -  Subjects with any active autoimmune disease or history of autoimmune disease;

          -  Uncontrolled clinically significant heart disease, including but not limited to the
             following: (1) &gt; NYHA II congestive heart failure; (2) unstable angina, (3) myocardial
             infarction within the past 1 year; (4) clinically significant supraventricular
             arrhythmia or ventricular arrhythmia requirement for treatment or intervention;

          -  Active infection or an unexplained fever &gt; 38.5°C during screening or before the first
             scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion
             of the investigator);

          -  Received a live vaccine within 4 weeks of the first dose of study medication;

          -  .Pregnancy or breast feeding;

          -  Decision of unsuitableness by principal investigator or physician-in- charge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Zhou, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Zhou, professor</last_name>
    <phone>0086-21-64041990</phone>
    <email>zhou.jian@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zheng Wang, professor</last_name>
    <phone>0086-21-64041990</phone>
    <email>wzdoc@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Zhou, professor</last_name>
      <phone>0086-21-64041990</phone>
      <email>zhou.jian@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zheng Wang, professor</last_name>
      <phone>0086-21-64041990</phone>
      <email>wzdoc@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jian Zhou, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zheng Wang, professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-1 Antibody</keyword>
  <keyword>Apatinib and Capecitabine</keyword>
  <keyword>Intrahepatic Cholangiocarcinoma</keyword>
  <keyword>Adjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

